UnitedHealth says needs more information to decide on coverage policy for Biogen's Alzheimer's drug - CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Biogen (BIIB) PT Lowered to $400 at BofA Securities
July 16, 2021 8:25 AM EDTBofA Securities analyst Geoff Meacham lowered the price target on Biogen (NASDAQ: BIIB) to $400.00 (from $415.00) while maintaining a Neutral rating on commercial headwinds.
... MoreExpert Panel Unanimously Decides Biogen's (BIIB) Aduhelm Offers no Patient Benefit
July 15, 2021 5:38 PM EDT(Updated - July 15, 2021 6:00 PM EDT)
Shares of Biogen (NASDAQ: BIIB) are losing 3% after-hours following a unanimous vote by a panel of prominent medical experts claiming the company's recently approved Alzheimer's drug Aduhelm offers no patient benefit.
In a recent meeting held by the... More
UnitedHealth Group (UNH) PT Raised to $450 at Cantor Fitzgerald
July 15, 2021 12:14 PM EDTCantor Fitzgerald analyst Steven Halper raised the price target on UnitedHealth Group (NYSE: UNH) to $450.00 (from $425.00) while maintaining an Overweight rating.
The analyst commented, "We reiterate our Overweight rating on UNH shares and increase our 12-month price target to $450 from $425. This morning, July 15, 2021, the company reported 2Q21... More
